<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795517</url>
  </required_header>
  <id_info>
    <org_study_id>HSK31679-201</org_study_id>
    <nct_id>NCT05795517</nct_id>
  </id_info>
  <brief_title>Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）</brief_title>
  <official_title>A Phase 2 ,Multicentre, Randomised, Double Blind Double Simulation, Placebo and Positive Controlled Study to Evaluate the Efficacy and Safety of HSK31679 in Patients With Hypercholesterolemia With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of HSK31679 tablets compared&#xD;
      with placebo in reducing low-density lipoprotein cholesterol (LDL-C) and MRI-PDFF after 12&#xD;
      weeks of treatment in patients with hypercholesterolemia and non-alcoholic fatty liver&#xD;
      disease (NAFLD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2023</start_date>
  <completion_date type="Anticipated">February 8, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 26, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in LDL-C from baseline at 12 week;</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percentage change in fasting low-density lipoprotein cholesterol (LDL-C) from baseline after 12 weeks of treatment;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage change in MRI-PDFF from baseline at 12 week；</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percentage change of MRI-PDFF(change in liver fat content by nuclear magnetic resonance - Proton Density Fat Fraction) from baseline after 12 weeks of treatment;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in fasting LDL-C from baseline;</measure>
    <time_frame>Week2,4,8</time_frame>
    <description>Percentage change in fasting low-density lipoprotein cholesterol (LDL-C) from baseline after 2, 4, and 8 weeks of treatment;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with MRI-PDFF decreased by &gt; 30%</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>After 12 weeks of treatment, the proportion of patients with MRI-PDFF decreased by &gt; 30%;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with LDL-C&lt;3.34mmol/L（&lt;130mg/dL）</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>After 12 weeks of treatment, the proportion of patients with LDL-C&lt;3.34mmol/L（&lt;130mg/dL）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of fasting TG from baseline;</measure>
    <time_frame>Week2,4,8,12</time_frame>
    <description>After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting triglycerides (TG), from baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of fasting TC from baseline;</measure>
    <time_frame>Week2,4,8,12</time_frame>
    <description>After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting total cholesterol (TC) from baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of fasting HDL-C from baseline;</measure>
    <time_frame>Week2,4,8,12</time_frame>
    <description>After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting high-density lipoprotein cholesterol (HDL-C) from baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in body weight from baseline</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percentage change in body weight from baseline after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-τ of HSK31679 (All subjects)</measure>
    <time_frame>up to 2,4,7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of HSK31679 (All subjects)</measure>
    <time_frame>up to 2,4,7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>HSK31679 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK31679 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK31679 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK31679 low dose</intervention_name>
    <description>HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12</description>
    <arm_group_label>HSK31679 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK31679 medium dose</intervention_name>
    <description>HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12</description>
    <arm_group_label>HSK31679 medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK31679 high dose</intervention_name>
    <description>HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12</description>
    <arm_group_label>HSK31679 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo ，QD，oral，Day1 to week 12</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10mg</intervention_name>
    <description>Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12</description>
    <arm_group_label>Ezetimibe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be willing to participate in the study and provide written informed consent.&#xD;
&#xD;
          2. Male or female aged 18 ≤ age &lt; 65 at the time of signing the informed consent.&#xD;
&#xD;
          3. At the time of screening, patients who had not received lipid-regulation therapy&#xD;
             within 6 weeks had fasting LDL-C≥3.34mmol/L（130mg/dL）.&#xD;
&#xD;
          4. (BMI) ≥18kg/m2 and female subjects ≥45.0 kg and male subjects ≥50.0 kg.&#xD;
&#xD;
          5. During screening, fasting triglyceride (TG) &lt;5.65 mmol/L.&#xD;
&#xD;
          6. During screening,MRI-PDFF≥8%.&#xD;
&#xD;
          7. Weight changes≤5% in the 4 weeks prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Did not discontinue any lipid-regulating therapy or any drug or supplement that may&#xD;
             affect lipid levels 6 weeks before randomization or is expected to do so during the&#xD;
             study period.&#xD;
&#xD;
          2. Homozygous familial hypercholesterolemia (HoFH) was diagnosed by genetic or clinical&#xD;
             criteria.&#xD;
&#xD;
          3. Dyslipidemia caused by other diseases or drugs, such as rheumatoid arthritis,&#xD;
             nephrotic syndrome, Cushing's syndrome, hypothyroidism, renal failure, systemic lupus&#xD;
             erythematosus, glycogen accumulation, myeloma, lipodystrophy, acute porphyria,&#xD;
             polycystic ovarian syndrome, etc&#xD;
&#xD;
          4. Before screening, LDL-C plasma exchange was performed within 12 months.&#xD;
&#xD;
          5. In the past, PCSK9 inhibitors, Lomitapide and Mipomersen were used for treatment.&#xD;
&#xD;
          6. uncontrolled hypertension had systolic blood pressure ≥160mmHg and/or diastolic blood&#xD;
             pressure ≥100mmHg at screening/baseline.&#xD;
&#xD;
          7. type 1 diabetes, or newly diagnosed type 2 diabetes within 1 month, or poorly&#xD;
             controlled type 2 diabetes, or who could not maintain the same hypoglycemic regimen&#xD;
             during the study.&#xD;
&#xD;
          8. Stroke or transient ischemic attack (TIA), acute coronary syndrome, stable angina&#xD;
             attack, severe deep vein thrombosis, or pulmonary embolism occurred in the 12 months&#xD;
             prior to screening.&#xD;
&#xD;
          9. Major surgery (including but not limited to: coronary or other revascularization,&#xD;
             coronary artery bypass surgery, and transplantation) within 12 months prior to&#xD;
             screening or planned during the study period.&#xD;
&#xD;
         10. Chronic systemic disease or history, including but not limited to&#xD;
&#xD;
               1. Have a serious cardiopulmonary disease or history,Neurological disease or&#xD;
                  history,Autoimmune disease,Chronic digestive disease or history&#xD;
&#xD;
               2. Have thyroid disease or symptomatic abnormalities in thyroid function tests&#xD;
                  (e.g., thyroid stimulating hormone (TSH) &lt; 1.0 x lower limit of normal (LLN) or &gt;&#xD;
                  1.5 x upper limit of normal (ULN))&#xD;
&#xD;
               3. History of malignancy (excluding cured basal cell carcinoma of the skin,&#xD;
                  carcinoma in situ, and papillary thyroid carcinoma) or history of antitumor&#xD;
                  therapy within 5 years prior to screening&#xD;
&#xD;
               4. Disease or medical history assessed by the investigator as likely to affect the&#xD;
                  study&#xD;
&#xD;
         11. Bariatric surgery within 12 months at the time of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>fangqiong Li</last_name>
    <phone>+8602867258840</phone>
    <email>lifangq@haisco.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>lai wei</last_name>
    <phone>+8613501038098</phone>
    <email>weelai@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tsinghua Changgeng in Beijing</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 9, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>May 7, 2023</last_update_submitted>
  <last_update_submitted_qc>May 7, 2023</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercholesterolemia</keyword>
  <keyword>non-alcoholic fatty liver disease(NAFLD)</keyword>
  <keyword>THR-β</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

